PRX933 hydrochloride is primarily investigated for its potential therapeutic applications in oncology, particularly as a selective inhibitor of the PI3K pathway, which plays a critical role in cell growth, survival, and proliferation. It shows promise in targeting tumors with specific genetic mutations such as PTEN loss or PIK3CA activation, commonly found in cancers like breast, prostate, and endometrial carcinomas. Due to its ability to cross the blood-brain barrier, it is also being studied in brain malignancies, including glioblastoma and brain metastases. Its hydrochloride salt form enhances solubility and bioavailability, supporting its use in oral dosing regimens in preclinical and clinical settings. Research continues to evaluate its efficacy both as a monotherapy and in combination with other anticancer agents.